

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
02 November 2023 (02.11.2023)



(10) International Publication Number
WO 2023/211939 A1

(51) International Patent Classification:

A61K 9/48 (2006.01) A61P 35/00 (2006.01)

A61K 31/138 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/US2023/019814

(22) International Filing Date:

25 April 2023 (25.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/334,845 26 April 2022 (26.04.2022) US

63/437,048 04 January 2023 (04.01.2023) US

(71) Applicant: **ATOSSA THERAPEUTICS, INC.** [US/US];
107 Spring Street, Seattle, Washington 98104 (US).

(72) Inventor: **QUAY, Steven C.**; c/o Atossa Therapeutics, Inc.,
107 Spring Street, Seattle, Washington 98104 (US).

(74) Agent: **HARWOOD, Melissa M.** et al.; DLA Piper
LLP, 701 Fifth Avenue, Suite 6900, Seattle, Washington
98104-7029 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: HIGH DOSE ENDOXIFEN FORMULATIONS AND METHODS OF USE




FIG. 1A

(57) Abstract: Described herein are pharmaceutical compositions comprising high doses of (Z)-endoxifen. A high dose endoxifen composition may be formulated to prevent crosslinking between the endoxifen active pharmaceutical ingredient and a surrounding layer, such as a capsule. The compositions may be further formulated as enteric resistant compositions for oral administration and delivery to an intestine of a subject. Also described herein are methods of treatment using high dose endoxifen compositions.